Demonstrating Fragment-Based Drug Discovery of ASTX029, a Dual Mechanism ERK1/2 Inhibitor
Time: 2:45 pm
day: Day 2 Track A PM
Details:
- Describing the fragment-based drug discovery of ASTX029, a dual-mechanism ERK1/2 (ERK) inhibitor that suppresses both the catalytic activity and phosphorylation of ERK
- Highlighting the opportunity that ASTX029 offers as a potent inhibitor of MAPK-activated tumor growth in preclinical models
- Showcasing ASTX029, which is currently undergoing clinical development in a Ph1/2 trial in advanced solid tumors
